FiercePharma9h
With narcolepsy trial win, Axsome looks to revive former Pfizer antidepressant on the US market
Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...
FiercePharma11h
Most life sciences CEOs expect to grow their head counts over the next 3 years: KPMG survey
On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...
FiercePharma8h
Kelun's Merck-partnered ADC snags first nod in China to kick off TROP2 fight with Gilead
Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...
FiercePharma8h
Sanofi opens $590M modular vaccine, biologics plant in Singapore
Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...
FiercePharma8h
FDA oncology advisory committee to weigh Exelixis' Cabometyx in neuroendocrine tumors
Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will ...